Frank B. Furnari

Growth suppression of glioma cells by PTEN requires a functional phosphatase catalytic domain.

In vitro loss of heterozygosity targets the PTEN/MMAC1 gene in melanoma.

The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells.

A novel seven transmembrane receptor induced during the early steps of astrocyte differentiation identified by differential expression.

Mutant epidermal growth factor receptor signaling down-regulates p27 through activation of the phosphatidylinositol 3-kinase/Akt pathway in glioblastomas.

Alix/AIP1 antagonizes epidermal growth factor receptor downregulation by the Cbl-SETA/CIN85 complex.

Cellular transformation by the MSP58 oncogene is inhibited by its physical interaction with the PTEN tumor suppressor.

PTEN: a novel anti-oncogenic function independent of phosphatase activity.

Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity.

PCAF modulates PTEN activity.

The efficacy of epidermal growth factor receptor-specific antibodies against glioma xenografts is influenced by receptor levels, activation status, and heterodimerization.

Malignant astrocytic glioma: genetics, biology, and paths to treatment.

Report from the fifth National Cancer Institute Mouse Models of Human Cancers Consortium Nervous System Tumors Workshop.

Activation of Src induces mitochondrial localisation of de2-7EGFR (EGFRvIII) in glioma cells: implications for glucose metabolism.

Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240.

A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments.

The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas.

Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA.

Therapeutic resistance in cancer: microRNA regulation of EGFR signaling networks.

Suppression of microRNA-9 by mutant EGFR signaling upregulates FOXP1 to enhance glioblastoma tumorigenicity.

A unified nomenclature and amino acid numbering for human PTEN.

A urokinase receptor-Bim signaling axis emerges during EGFR inhibitor resistance in mutant EGFR glioblastoma.

Cancer-associated protein kinase C mutations reveal kinase's role as tumor suppressor.

Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma.

Orthogonal targeting of EGFRvIII expressing glioblastomas through simultaneous EGFR and PLK1 inhibition.

EGFR Mutation Promotes Glioblastoma through Epigenome and Transcription Factor Network Remodeling.

The EGF Receptor Promotes the Malignant Potential of Glioma by Regulating Amino Acid Transport System xc(-).

An LXR-Cholesterol Axis Creates a Metabolic Co-Dependency for Brain Cancers.

Simultaneous blockade of interacting CK2 and EGFR pathways by tumor-targeting nanobioconjugates increases therapeutic efficacy against glioblastoma multiforme.

Inhibition of radiation-induced glioblastoma invasion by genetic and pharmacological targeting of MDA-9/Syntenin.

Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity.

PTEN regulates glioblastoma oncogenesis through chromatin-associated complexes of DAXX and histone H3.3.

Glioblastoma cellular cross-talk converges on NF-κB to attenuate EGFR inhibitor sensitivity.